Georgiana Luminiţa Fota

  • Citations Per Year
Learn More
HER-2/neu oncoprotein overexpression in breast cancer patients has an impact on prognosis and treatment methods so assessment of its status is therefore much needed. The study group consisted of 90 cases of mammary invasive carcinoma. The distribution of HER-2/neu immunoexpression for scores 0, 1+, 2+ and 3+ were 54.44%, 11.11%, 18.8% and 15.56%(More)
The identification of breast ductal carcinoma in situ (DCIS) is a factor that increases 8-10 times the risk of developing invasive ductal breast carcinoma (DCI) later. In this study, we evaluated the immunoexpression of the HER2/neu oncoprotein in the DCIS cases associated with DCI, both in situ and in the invasive components. We also studied the Her2/neu(More)
Our study was carried out on a total number of 158 patients, with a mean age of 32, all tested and identified cytologically (Pap-test) as presenting minor cellular abnormalities, respectively ASCUS (10) and LSIL (119), and major cellular abnormalities, respectively SIL-borderline (8) and HSIL (21), and who, either voluntarily or upon cytopathologists'(More)
  • 1